<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01613456</url>
  </required_header>
  <id_info>
    <org_study_id>PEC11010</org_study_id>
    <secondary_id>ID RCB: 2011-A00915-36</secondary_id>
    <nct_id>NCT01613456</nct_id>
  </id_info>
  <brief_title>Effect of Saccharomyces Cerevisiae on the Symptoms of Irritable Bowel Syndrome</brief_title>
  <official_title>Effect of S.Cerevisiae vs Placebo on the Improvement of Gastrointestinal Disorders,Especially During Irritable Bowel Syndrome. Randomized, Double-blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lesaffre International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioFortis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lesaffre International</source>
  <brief_summary>
    <textblock>
      The main purpose of this study is the effect of the probiotic yeast Saccharomyces cerevisiae
      CNCM I-3856 on abdominal pain or intestinal discomfort in patients presenting with the
      irritable bowel syndrome (IBS)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in discomfort score,obtained by Daily Likert Scale averaged by week</measure>
    <time_frame>baseline and week 8</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">364</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dicalcium phosphate, Maltodextrin and Magnesium stearate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saccharomyces cerevisiae CNCM I-3856</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Saccharomyces cerevisiae CNCM I-3856</intervention_name>
    <description>2 capsules/day during 12 weeks</description>
    <arm_group_label>Saccharomyces cerevisiae CNCM I-3856</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule with comparable organoleptic properties and weight than the experimental product.
2 capsules/day during 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  IBS subject meeting the Rome III criteria , with a discomfort or pain present more
             than 1 day per week in whom organic causes of their symptoms have been excluded

          -  IBS-C with less than 3 complete spontaneous bowel movements/week

          -  IBS-D with at least 2 or more days/week one stool which has consistency of type 6 or 7
             Bristol stool score

          -  Subject able of and willing to comply with the protocol and to give their written
             informed consents

        Exclusion criteria:

          -  History of chronic gastrointestinal disorders

          -  History of lactose intolerance

          -  History of gluten intolerance

          -  Treatment able to influence IBS, modifying intestinal sensitivity and motility
             (antidepressants,opioid, narcotic analgesics)

          -  Eating disorders

          -  Pregnancy in progress
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David GENDRE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BioFortis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robin SPILLER, Professor of Gastroenterology</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nottingham Digestive Diseases Centre University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biofortis</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2012</study_first_submitted>
  <study_first_submitted_qc>June 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2012</study_first_posted>
  <last_update_submitted>May 13, 2015</last_update_submitted>
  <last_update_submitted_qc>May 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

